Filing Flows › Protalix BioTherapeutics (PLX) › LICENSE AND R&D SERVICES revenue
Protalix BioTherapeutics (PLX) LICENSE AND R&D SERVICES revenue by quarter
Protalix BioTherapeutics' LICENSE AND R&D SERVICES revenue was $68K in Q2 2026 (second quarter 2026), -100% from Q1 2026. Over the last 7 quarters it ranged from $57K (Q4 2024) to $26.3M (Q1 2026).
| Quarter | LICENSE AND R&D SERVICES revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $68K | -100% | -69% |
| Q1 2026 | $26.3M | 62× | 223× |
| Q4 2025 | $428K | +140% | +651% |
| Q3 2025 | $178K | -18% | — |
| Q2 2025 | $218K | +85% | — |
| Q1 2025 | $118K | +107% | — |
| Q4 2024 | $57K | — | — |
Q2 2026 at a glance
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protalix BioTherapeutics' LICENSE AND R&D SERVICES revenue?
Protalix BioTherapeutics' LICENSE AND R&D SERVICES revenue was $68K in Q2 2026 (second quarter 2026), -100% from Q1 2026.
How has Protalix BioTherapeutics' LICENSE AND R&D SERVICES revenue changed?
Over the last 7 quarters it ranged from $57K (Q4 2024) to $26.3M (Q1 2026).
Q2 2026 results → · How Protalix BioTherapeutics makes money →